Trials / Completed
CompletedNCT00319553
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 647 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 11 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed | 0.5 mL, IM |
| BIOLOGICAL | BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed | 0.5 mL, IM |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2008-10-01
- Completion
- 2008-12-01
- First posted
- 2006-04-27
- Last updated
- 2012-10-05
- Results posted
- 2010-10-21
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00319553. Inclusion in this directory is not an endorsement.